TREATMENT OF MIGRAINE
The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 30. Juni Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
TRUGMAN JOEL [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-06-30, Last update posted on www.tib.eu: 2024-02-23, Last updated: 2024-03-01 |
|---|
| Patentnummer: |
WO2022140537 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA014689456 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA014689456 | ||
| 003 | DE-627 | ||
| 005 | 20240301101234.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA014689456 | ||
| 035 | |a (EPA)WO2022140537 | ||
| 035 | |a (EPA)82021866 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a TRUGMAN JOEL |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TREATMENT OF MIGRAINE |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-06-30, Last update posted on www.tib.eu: 2024-02-23, Last updated: 2024-03-01 | ||
| 520 | |a The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a BOINPALLY RAMESH |4 aut | |
| 700 | 0 | |a JAKATE ABHIJEET |4 aut | |
| 700 | 0 | |a FINNEGAN MICHELLE |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 30. Juni |
| 773 | 1 | 8 | |g year:2022 |g day:30 |g month:06 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/82021866/publication/WO2022140537A1?q=WO2022140537 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 30 |c 06 | ||